Table 1 Clinical and laboratory findings in the studied patients (n = 100)
|  | All patients N = 100 | Diaphragmatic dysfunction + ve n = 43 | Diaphragmatic dysfunction −ve n = 57 | p value |
|---|---|---|---|---|
Age (years) mean ± SD | 60.7 ± 8.7 | 60.5 ± 9.1 | 60.9 ± 8.5 | 0.83 |
Male/female n (%) | 55 (55.0)/45 (45.0) | 29 (67.4)/14 (32.6) | 26 (45.6)/31(54.4) | 0.03 |
BMI (Kg/m2) | 25.2 ± 3.8 | 23.8 ± 3.8 | 26.3 ± 3.5 |  < 0.001 |
Comorbidities n (%) | ||||
HTN | 54 (54.0) | 22 (51.2) | 32 (56.1) | 0.62 |
DM | 41 (41.0) | 18 (41.9) | 23 (40.4) | 0.88 |
RA | 15 (15.0) | 6 (14.0) | 9 (15.8) | 0.8 |
SLE | 8 (8.0) | 5 (11.6) | 3 (5.3) | 0.25 |
HD duration (months) mean ± SD | 72.4 ± 40.0 | 82.2 ± 42.1 | 64.8 ± 36.9 | 0.031 |
Malnutrition n (%) | ||||
No/Mild | 34 (34.0) | 8 (18.6) | 31 (54.4) | 0.005 |
Moderate/severe | 66 (66.0) | 35 (81.4) | 26 (45.6) | |
Laboratory findings mean ± SD/median (IQR) | ||||
Hb (gm/dL) | 10.0 ± 1.5 | 9.6 ± 1.5 | 10.3 ± 1.4 | 0.011 |
WBCs (× 103/mL) | 6.1 ± 2.0 | 6.4 ± 2.0 | 5.8 ± 1.9 | 0.09 |
Platelets (× 103/mL) | 196.7 ± 58.5 | 190.4 ± 65.0 | 201.5 ± 53.2 | 0.35 |
Creatinine (mg/dL) | 7.8 ± 2.5 | 7.5 ± 2.4 | 8.0 ± 2.5 | 0.31 |
Urea (mg/dL) | 112.7 ± 32.1 | 115.2 ± 33.0 | 110.8 ± 31.6 | 0.5 |
FBS (mg/dL) | 125.3 ± 46.7 | 127.6 ± 49.2 | 123.6 ± 45.1 | 0.67 |
Albumin (gm/dL) | 3.8 ± 0.6 | 3.4 ± 0.4 | 4.1 ± 0.5 |  < 0.001 |
Cholesterol (mg/dL) | 171.5 ± 48.2 | 183.4 ± 52.9 | 162.5 ± 42.6 | 0.031 |
Triglycerides (mg/dL) | 181.8 ± 107.4 | 194.7 ± 113.1 | 172.0 ± 102.8 | 0.29 |
Calcium (mg/dL) | 8.8 ± 0.8 | 8.4 ± 0.8 | 9.0 ± 0.7 |  < 0.001 |
Phosphorus (mg/dL) | 4.5 ± 1.2 | 4.2 ± 1.1 | 4.7 ± 1.3 | 0.067 |
Sodium (mEq/L) | 136.2 ± 5.7 | 133.0 ± 5.2 | 138.6 ± 4.8 |  < 0.001 |
Potassium (mEq/L) | 4.7 ± 0.6 | 4.4 ± 0.6 | 4.7 ± 1.3 |  < 0.001 |
iPTH (pg/mL) | 366.5 (187.0–909.8) | 395.0 (206.0–904.0) | 338.0 (175.0–930.0) | 0.79 |
Uric acid (mg/dL) | 5.9 ± 1.3 | 6.0 ± 1.4 | 5.8 ± 1.2 | 0.61 |
hsCRP (mg/L) | 100.6 (75.9–116.6) | 113.6 (90.9–130.4) | 91.1 (50.9–105.6) |  < 0.001 |